Days after Russian Covid-19 vaccine trial approval, information breach forces Dr. Reddy’s vegetation shut – Home Health Choices
Pharma main Dr. Reddy's Laboratories shut down its manufacturing services…Latest Updates
PUNE: The phase-III human scientific trial of the COVID-19 vaccine developed by Oxford University and being manufactured by the Serum Institute of India (SII) will start on the Sassoon General Hospital in Pune subsequent week.
Dean of the state-run Sassoon General Hospital Dr Muralidhar Tambe informed this to PTI on Saturday.
“The phase-III trial of ‘Covishield’ vaccine will begin at Sassoon hospital from next week. It is likely to start on Monday. Some volunteers have already come forward for the trial. Around 150 to 200 volunteers will be administered the vaccine candidate dose,” he stated.
“From Saturday, the hospital started enrolling volunteers for the trial. Those who are willing to volunteer for the vaccination should contact the hospital,” he stated.
Under phase-II, trials have been performed at Bharti Vidyapeeth Medical College and likewise KEM Hospital within the metropolis.
The SII has partnered with British-Swedish pharma firm AstraZeneca for manufacturing the COVID-19 vaccine candidate, developed by the University of Oxford.
Earlier this month, the SII had paused the scientific trials of the vaccine candidate within the nation.
The Drugs Controller General of India (DCGI) had on September 11 directed the SII to droop any new recruitment within the phase-II and III scientific trial of the vaccine until additional orders after AstraZeneca paused the trials in different nations due to “an unexplained illness” in a participant within the research.
However, on September 15, the DCGI gave permission to the SII to renew scientific trial of the vaccine.